Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:728983.
doi: 10.1155/2012/728983. Epub 2011 Dec 15.

New acetylcholinesterase inhibitors for Alzheimer's disease

Mona Mehta  1 , Abdu Adem, Marwan Sabbagh
Affiliations

New acetylcholinesterase inhibitors for Alzheimer's disease

Mona Mehta et al. Int J Alzheimers Dis. 2012.

Abstract

Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia gravis had effectively proven that AchE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEI) continue to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs in development and their respective mechanisms of actions. This pharmacological approach continues to be active with many promising compounds.

PubMed Disclaimer

References

    1. Orhan G, Orhan I, Öztekin-Subutay N, Ak F, Şener B. Contemporary anticholinesterase pharmaceuticals of natural origin and their synthetic analogues for the treatment of Alzheimer’s disease. Recent Patents on CNS Drug Discovery. 2009;4(1):43–51. - PubMed
    1. Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C. Tacrine derivatives and Alzheimer’s disease. Current Medicinal Chemistry. 2010;17(17):1825–1838. - PubMed
    1. Fernández-Bachiller MI, Pérez C, González-Muñoz GC, et al. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimers disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. Journal of Medicinal Chemistry. 2010;53(13):4927–4937. - PubMed
    1. Tacrine. Drugs in Clinical Trials. Alzheimer Research Forum, http://www.alzforum.org/drg/drc/detail.asp?id=90.
    1. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Archives of Internal Medicine. 1998;158(9):1021–1031. - PubMed

LinkOut - more resources